Gamida Cell Ltd. (NASDAQ:GMDA) Q4 2023 Earnings Conference Call March 27, 2023 8:00 AM ET
Company Participants
Abigail Jenkins - President and Chief Executive Officer
Ronit Simantov - Chief Medical and Chief Scientific Officer
Michele Korfin - Chief Operating and Chief Commercial Officer
Shai Lankry - Chief Financial Officer
Conference Call Participants
Edward Tenthoff - Piper Sandler
Jonathan Miller - Evercore ISI
Mark Breidenbach - Oppenheimer
Jason Butler - JMP Securities
Vernon Bernardino - H.C. Wainwright
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell's Conference Call for the Full Year 2022 Financial Results. My name is Catherine and I'll be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell's request.
I would now like to introduce your host for today Mike Ciskowski of Gamida Cell, Corporate Communications. Please go ahead.
Unidentified Company Representative
Thank you, Catherine, and good morning, everyone. Welcome to today's call during which we will provide an update on the company and review our financial results for the full year of 2022.
Earlier this morning, we issued a press release summarizing our financial results and providing a business update, which is available on our website at www.gamidacell.com. Here with me on our call today are Abi Jenkins, President and Chief Executive Officer; Ronit Simantov, Chief Medical Officer and Scientific Officer; Michele Korfin, Chief Operating Officer and Chief Commercial Officer; and Shai Lankry, Chief Financial Officer.
During this call, we may make forward-looking statements about our future expectations and plans including with respect of the timing and initiation and progress of and data reported from the preclinical and clinical trials of our product candidates, regulatory filings, including the review of the BLA for Omidubicel by the FDA, commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell's product candidates, including GDA-201 and Omidubicel, and our expectations regarding our projected cash, cash equivalent, and investment to be used for operating activities.
Our actual results may differ materially from what we project today due to a number of important factors, the scope, progress and expansion of our clinical trials and impacts to the cost thereof. Scientific, clinical, regulatory and technical developments, those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics and in the endeavor of building a business around such product candidates as well as those considerations described in the Risk Factors section of our most recent quarterly report on Form 10-Q and other filings that we make with the SEC from time-to-time.